DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter

CUPERTINO, Calif., June 27, 2019 -- (Healthcare Sales & Marketing Network) -- DURECT Corporation (Nasdaq: DRRX) today announced it has submitted a full response to the Complete Response Letter (CRL) it previously received from U.S. Food and Drug Administr... Biopharmaceuticals, Drug Delivery, FDA DURECT, POSIMIR, bupivacaine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news